Parabilis Medicines, Inc. Stock-Based Compensation
Parabilis Medicines, Inc. (PBLS) reported Stock-Based Compensation of $4.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- 2026-06-30: Share-based Payment Arrangement, Noncash Expense 6 month $4.94M.
- 2025-06-30: Share-based Payment Arrangement, Noncash Expense 6 month $1.68M.
| Period end | Share-based Payment Arrangement, Noncash Expense 6 month |
|---|---|
| 2026-06-30 | $4.94M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-13 |